TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain in the Morning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of presumed acute kidney rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of presumed acute pancreas rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of kidney graft loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of pancreas graft loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lupus serology (ANA, dsDNA, C3, C4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal function (GFR, BUN, urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concordance between online and offline assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of diagnosis agreement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of management plan agreement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Substance use and high-risk transmission behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical engagement and outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial indices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in non-inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysferlin protein expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway Blood Flow Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transvaginal sonographic sliding sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity level measured by actimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Free Survival Events
Endpoint domain: Mortality/survival
Primary endpoint: Surgery-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite clinical endpoint of cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of patient adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular diastolic function assessment (ASE recommendations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular diastolic function assessment (EACVI recommendations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrhythmia detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of V3381
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events (AE) / serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in vital signs and ECG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain MRI findings for amyloid-related imaging abnormalities (ARIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Automated REM without atonia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of Augment Bone Graft plus Allograft
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hours of crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health Outcome Improvement Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Patients With Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Ascites worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement (histological) of glandular atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of metachronous gastric cancer
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of cancelled cardiac surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diaphragm movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aerobic capacity (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst formation potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Achieving a Seroconversion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first asthma medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (TAU) for ethinyl estradiol, norelgestromin, and norgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-Tb test positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Eating Disorder symptomatology I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Disorder symptomatology II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global score of the mini-RQLQ at visit 2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shift across the board of National Institute of Health stroke scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shift across the board of Modified Rankin Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduced inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perceived personal control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cancer genetic knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maximum tolerated dose of intravenous emulsion 4-HPR
Endpoint domain: Adverse events/effects
Primary endpoint: Functioning of AVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD-MRI signal intensity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug concentration-time curve from time 0 to last measurable concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical dyssynchrony quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain 5 years after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sports function 5 years after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of osteoarthritis 5 years after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Numbers of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of high grade embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade 3 or Greater Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Time to readiness for PACU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of ICU survivors
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Alive Without Respiratory Failure at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Percent of Possible Self-Reported Skin Care Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Behavior Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Any Skin Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of H. pylori Clarithromycin resistance gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acceptance of communication mode
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in contrast-enhancing lesions on brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participant completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant qualitative feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systemic Lupus Activity Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) related to Study Drug Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of System Specific Grade 3 or Higher Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Acute and Chronic Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Glucose Disposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In-hospital Delirium-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke and changes in number of micro cerebral infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transmitral pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Warwick Edinburgh Mental Well-being Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in FACE-Q - Appearance-related psychosocial distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in FACE-Q - Satisfaction with outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in FACE-Q -Psychological function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Memory and Learning Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ProHema modulated umbilical cord blood units
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence on therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hand perfusion measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian follicular development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Estradiol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disease Accrual damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary tumor maximum diameter changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in intraesophageal H+ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in intragastric H+ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathologic Response at Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in log transformed blood urea nitrogen (BUN)/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of days to engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluation of centers training and knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: behavior, perception, fears and appreciation degree linked to new technology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vertebral Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete healing of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cosmetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tooth Root Caries Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained 50% Reduction in the Number of Cig/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of peripheral vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to First Adjudicated ISTH MBE or CRNMBE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciprofloxacin plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Population pharmacokinetic (PK) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global quality scale QL2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score of the serious game
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the serious game
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with a partial or complete response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chronic GVHD- and relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Brain structural changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain functional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical attachment level change (CALC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥3 Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders with a Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: FLT-PET Activity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of patients eligible for clinical trials and targeted therapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Brief Psychiatric Rating Scale (BPRS) total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in maternal vitamin D status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone fracture incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary levels of glucoraphanin or sulforaphane and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional MRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 (Disease Activity Score 28-joint count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAPSA (Disease Activity Index for Psoriatic Arthritis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of a Single Dose of 250 mg Androxal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Change in log10 Colony-forming Unit (CFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Daily Change in Time to Positivity (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: INH PK Parameter Area Under the Concentration Time Curve (AUC 0-24 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 2 or Higher Drug-related Adverse Clinical or Laboratory Events
Endpoint domain: Adverse events/effects
Primary endpoint: Negative symptoms in schizophrenia or schizoaffective disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of recent chemsex practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fMRI BOLD response of visual plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity resulting from radiation treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of trūFreeze® spray cryotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of trūFreeze® spray cryotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Stroke (Disabling)
Endpoint domain: Mortality/survival
Primary endpoint: Device Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ad libitum intake of a later lunch meal (calories - kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of stillbirths with GBS isolation
Endpoint domain: Mortality/survival
Primary endpoint: Shoulder dislocation recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in laboratory values, vital signs, physical exam, and electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom distress related to LPR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effects of LPR on voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of LPR on swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to discomfort due to watering
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: common adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: drug-to-drug interaction adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: dose modifications
Endpoint domain: Adverse events/effects
Primary endpoint: Upper limb Fugl-Meyer scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death and heart failure rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants having treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to maximum plasma concentration (Tmax) of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (Phase 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes